REMOVAL trial makes 2018 American Diabetes Association “Standards of Medical Care”
Improving cardiovascular risk factors with metformin in type 1 diabetes - as shown in Prof John Petrie’s recent REMOVAL trial (Lancet Diabetes and Endocrinology August 2017, Pubmed ID 28615149 http://eprints.gla.ac.uk/143027) - has been added to the annual update of the American Diabetes Association’s guideline document: http://care.diabetesjournals.org/content/41/Supplement_1/S73.full-text.pdf.
Prof Petrie said: “Although metformin is not licensed in type 1 diabetes, the results of REMOVAL are already changing the ways in which diabetologists are treating this condition.”
Amongst 18 citations to date, REMOVAL has been:
- cited in an editorial in the New England Journal of Medicine (Pubmed ID 28899219) on “Adjunctive Treatments for Type 1 Diabetes”
- the subject of a short review on “Cardiovascular Benefits of Metformin in T1DM” in Nature Reviews (Endocrinology) (Pubmed ID 28895950)
-incorporated into a 2018 meta-analysis of metformin in type 1 diabetes in Diabetes Metabolism Research Reviews (Pubmed 29351716).
Prof Petrie and the REMOVAL team are now working on further outcomes and analyses, some of which will be presented at the 2018 Diabetes UK Annual Professional Conference (ExCeL London, Wednesday 14th March, 17.00 pm).
First published: 26 February 2018